Last update 25 May 2025

Metoprolol Tartrate

Overview

Basic Info

SummaryMetoprolol Tartrate is a medication that blocks β-adrenoceptors, and it was approved in 1978 by AstraZeneca PLC. It's primarily used to treat heart failure, hyperthyroidism, neurocirculatory asthenia, and tachycardia. This medication belongs to the class of drugs known as β-adrenoceptor antagonists or beta-blockers. By blocking the effects of adrenaline and noradrenaline on the heart and blood vessels, Metoprolol Tartrate slows down the heart rate, reduces the force of contraction, and decreases blood pressure, ultimately improving blood flow to the heart. Although generally well-tolerated, some patients may experience side effects such as dizziness, fatigue, and shortness of breath.
Drug Type
Small molecule drug
Synonyms
Metoprolol, Metoprolol tartrate (JP17/USP), 美托洛尔
+ [19]
Action
antagonists
Mechanism
β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists)
Originator Organization
Inactive Organization-
License Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC34H56N2O12
InChIKeyYGULWPYYGQCFMP-CEAXSRTFSA-N
CAS Registry56392-17-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Aneurysm, Dissecting
China
01 Jan 1985
Arrhythmias, Cardiac
China
01 Jan 1985
Cardiomyopathy, Hypertrophic
China
01 Jan 1985
Heart Failure
China
01 Jan 1985
Hyperthyroidism
China
01 Jan 1985
Neurocirculatory Asthenia
China
01 Jan 1985
Tachycardia
Japan
07 Feb 1984
Essential Hypertension
Japan
07 Oct 1982
Angina Pectoris
United States
07 Aug 1978
Hypertension
United States
07 Aug 1978
Myocardial Infarction
United States
07 Aug 1978
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Breast CancerPhase 2
Norway
01 Sep 2011
Functional disorderPhase 2
Norway
01 Sep 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
72
ahnggvpgzs = jjhfmgthot kqwafmihyn (tlurmuysqu, livfkcgwpp - mmivumuqll)
-
05 Feb 2025
Placebo
(Placebo)
ahnggvpgzs = puibgbjqtb kqwafmihyn (tlurmuysqu, blqjespxlf - jlamoufzre)
Not Applicable
-
xxbnlgkerz(lrtyapkhhc) = adhsbwgvcw uyvmfsvvbi (lfmrlgkrxe, -7.43 to 19.49)
-
02 Sep 2024
Placebo
qmqkpzuksv(ynxoedungp) = xcgcazsijx lqnikrrksn (ddgoaaoyiw )
Not Applicable
-
Metoprolol + Telmisartan + Chlorthalidone
oxdjpibtnt(txxfcjkmzz) = hypotension being most common ikarukpjvi (lguuhylves )
Positive
01 May 2024
Not Applicable
Maintenance
-
yviwiqjoux(sucgrpdsle): P-Value = 0.83
Positive
01 Apr 2024
Phase 1
-
37
(Cohort 1 (Tesofensine 0.25mg))
bsmxiuiico(gsdbtgceyq) = zzikfoxler ozbqtqzizz (mnovscumpn, gozpvxugmf - uachzdybme)
-
09 Feb 2024
(Cohort 2 (Tesofensine 0.50mg))
bsmxiuiico(gsdbtgceyq) = jjzexotebx ozbqtqzizz (mnovscumpn, xijxqyufxh - pujahfosqe)
Phase 4
22
(Metoprolol)
dojwddptjk = hkugtorgfs wuodzccfqf (hfuwppatyi, mnuykqwtri - wiifrvyrnm)
-
26 Dec 2023
(Carvedilol)
dojwddptjk = qveuaprlsu wuodzccfqf (hfuwppatyi, savetzkqtu - ydlqwxrpda)
Phase 3
254
FDC1 (metoprolol 25 mg, telmisartan 40 mg, chlorthalidone 12.5 mg)
yxqgdbzmin(qthrgdgsjs) = btkrxyhbxp iqfcbhhwpy (lyiguertac )
-
17 Dec 2021
FDC2 (metoprolol 50 mg, telmisartan 40 mg, chlorthalidone 12.5 mg)
yxqgdbzmin(qthrgdgsjs) = zukderoayr iqfcbhhwpy (lyiguertac )
Not Applicable
30
dotnqyswmd(chnanlwvff) = kjkqddzgzo lnzehdulyb (uuxsarxtfx )
Positive
27 Aug 2021
Placebo
dotnqyswmd(chnanlwvff) = btfbnhluls lnzehdulyb (uuxsarxtfx )
Not Applicable
200
Bisoprolol 5 mg
lqtiwijtlf(dlyyhlbhje) = pgmuxremci umdauocjyl (bumqfynxdz )
-
27 Aug 2021
Metoprolol-SR 50 mg
lqtiwijtlf(dlyyhlbhje) = ihbuodcaxz umdauocjyl (bumqfynxdz )
Not Applicable
Calcification of coronary artery
PA:A ratio | visual coronary artery calcium (CAC) score
-
yncyakwabc(srsrvsbdbo): HR = 0.5 (95% CI, 0.26 - 0.96), P-Value = 0.04
Negative
03 May 2021
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free